$7.21 Million in Sales Expected for OptimizeRx Co. (NASDAQ:OPRX) This Quarter
Equities research analysts expect that OptimizeRx Co. (NASDAQ:OPRX) will report $7.21 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for OptimizeRx’s earnings, with the highest sales estimate coming in at $7.31 million and the lowest estimate coming in at $7.15 million. OptimizeRx posted sales of $5.42 million in the same quarter last year, which suggests a positive year-over-year growth rate of 33%. The business is expected to issue its next quarterly earnings results on Monday, November 4th.
On average, analysts expect that OptimizeRx will report full-year sales of $28.72 million for the current fiscal year, with estimates ranging from $28.47 million to $28.87 million. For the next year, analysts anticipate that the firm will post sales of $37.59 million, with estimates ranging from $37.15 million to $38.42 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for OptimizeRx.
OptimizeRx (NASDAQ:OPRX) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.03 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.03. OptimizeRx had a return on equity of 2.89% and a net margin of 2.27%. The business had revenue of $7.01 million for the quarter, compared to the consensus estimate of $6.78 million.
A number of hedge funds have recently made changes to their positions in the stock. Park West Asset Management LLC grew its stake in OptimizeRx by 14.0% during the 2nd quarter. Park West Asset Management LLC now owns 1,088,088 shares of the company’s stock worth $17,627,000 after buying an additional 133,238 shares during the last quarter. Marshall Wace LLP grew its stake in OptimizeRx by 62.6% during the 2nd quarter. Marshall Wace LLP now owns 94,769 shares of the company’s stock worth $1,535,000 after buying an additional 36,475 shares during the last quarter. Vanguard Group Inc. grew its stake in OptimizeRx by 22.2% during the 2nd quarter. Vanguard Group Inc. now owns 511,060 shares of the company’s stock worth $8,279,000 after buying an additional 93,015 shares during the last quarter. Venator Capital Management Ltd. grew its stake in OptimizeRx by 2.6% during the 2nd quarter. Venator Capital Management Ltd. now owns 214,000 shares of the company’s stock worth $3,467,000 after buying an additional 5,521 shares during the last quarter. Finally, BlackRock Inc. grew its stake in OptimizeRx by 2,111.6% during the 2nd quarter. BlackRock Inc. now owns 607,292 shares of the company’s stock worth $9,839,000 after buying an additional 579,833 shares during the last quarter. Hedge funds and other institutional investors own 56.14% of the company’s stock.
OPRX stock traded up $0.13 on Tuesday, hitting $15.65. 177,070 shares of the company’s stock were exchanged, compared to its average volume of 104,732. OptimizeRx has a 12-month low of $8.92 and a 12-month high of $18.14. The firm has a 50 day moving average price of $15.43 and a two-hundred day moving average price of $14.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.80 and a current ratio of 6.80. The stock has a market cap of $219.41 million, a P/E ratio of 313.00, a price-to-earnings-growth ratio of 1.76 and a beta of 0.45.
OptimizeRx Company Profile
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.
Recommended Story: How is inflation measured?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.